--- title: "ENANTA PHARMACEUTICALS INC 3Q 2026: Revenue $17.16M, EPS $(0.45) — 10-Q Summary" type: "News" locale: "en" url: "https://longbridge.com/en/news/286249442.md" description: "Enanta Pharmaceuticals Inc reported Q3 2026 revenue of $17.16M, a 15% increase from $14.93M in the previous year. The net loss narrowed to $13.09M from $22.64M, with diluted EPS improving to $(0.45) from $(1.06). Royalty revenue rose due to higher MAVYRET/MAVIRET sales. The RSV program showed positive Phase 2b results, and the immunology pipeline advanced with EDP-978 entering Phase 1. Cash and marketable securities stand at $227M, supporting development through fiscal 2029." datetime: "2026-05-13T11:11:00.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286249442.md) - [en](https://longbridge.com/en/news/286249442.md) - [zh-HK](https://longbridge.com/zh-HK/news/286249442.md) --- # ENANTA PHARMACEUTICALS INC 3Q 2026: Revenue $17.16M, EPS $(0.45) — 10-Q Summary Enanta Pharmaceuticals Inc reported third-quarter fiscal 2026 results with revenue of $17.16M and a net loss that narrowed versus the year-ago quarter, reflecting stronger royalty receipts and continued investment in its RSV and immunology programs. **Financial Highlights** - Revenue was $17.159M for Q3 2026, compared with $14.926M in the year-ago quarter; YoY change 15.0%. - Net income (loss) was a loss of $13.091M for Q3 2026, compared with a loss of $22.644M in the year-ago quarter; improvement year over year. - Diluted earnings per share was $(0.45) for Q3 2026, compared with $(1.06) per share in the year-ago quarter; improvement year over year. **Business Highlights** - Royalty revenue momentum: Royalty revenue rose year over year, driven by higher MAVYRET/MAVIRET sales and a U.S. acute HCV label expansion; revenue was $17.2M in the quarter and $35.8M year-to-date. - RSV program progress: Zelicapavir reported positive Phase 2b topline results in high‑risk adults and positive pediatric topline results; the company is planning a pivotal study and engaging with the FDA. - Immunology pipeline advances: EDP‑978 entered Phase 1 single- and multiple-ascending dose dosing; STAT6 candidate EPS‑3903 is on track for an IND in H2 2026; selection of an MRGPRX2 preclinical candidate is planned for H2 2026. - R&D spending shift: Overall R&D decreased due to RSV trial timing while investments increased in immunology and early discovery to reflect pipeline prioritization. - Liquidity outlook: Cash and marketable securities of $227M provide a development runway into fiscal 2029 per management guidance. Original SEC Filing: ENANTA PHARMACEUTICALS INC \[ ENTA \] - 10-Q - May. 13, 2026 **Disclaimer** This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC. ### Related Stocks - [ENTA.US](https://longbridge.com/en/quote/ENTA.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md) - [IHE.US](https://longbridge.com/en/quote/IHE.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [VHT.US](https://longbridge.com/en/quote/VHT.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) - [XLV.US](https://longbridge.com/en/quote/XLV.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) ## Related News & Research - [Enanta Pharma's RSV Bet And Immunology Ambitions](https://longbridge.com/en/news/286895623.md) - [](https://longbridge.com/en/news/286807703.md) - [Corvus Pharmaceuticals presents Phase 1 soquelitinib data showing durable remissions, favorable safety](https://longbridge.com/en/news/286404245.md) - [Eton Pharmaceuticals Q1 product sales rise driven by portfolio expansion](https://longbridge.com/en/news/286461579.md) - [](https://longbridge.com/en/news/286601439.md)